Broadcom Inc
Change company Symbol lookup
Select an option...
AVGO Broadcom Inc
VZ Verizon Communications Inc
SPVU Invesco S&P 500® Enhanced Value ETF
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
SPG Simon Property Group Inc
SPFF Global X SuperIncome™ Preferred ETF
SPDV AAM S&P 500 High Dividend Value ETF
SOXS Direxion Daily Semiconductor Bear 3X Shares
SOXL Direxion Daily Semiconductor Bull 3X Shares
SOLOW Electrameccanica Vehicles Corp *W EXP 08/13/2023
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Based in Singapore
Company profile

Broadcom Inc. is a technology company. The Company designs, develops and supplies a range of semiconductor and infrastructure software solutions. It operates through two segments: semiconductor solutions and infrastructure software. Its semiconductor solutions segment includes semiconductor solution product lines, as well as its Internet protocol (IP) licensing. Its infrastructure software segment includes its mainframe and enterprise software solutions and fiber channel storage area networking business. It develops semiconductor devices with a focus on digital and mixed signal complementary metal oxide semiconductor (CMOS) based devices and analog III-V based products. It provides semiconductor solutions for managing the movement of data in data center, telecom, enterprise, and embedded networking applications. Its mainframe software solutions include solutions for the IBM Z mainframe platform, which runs business applications.

Closing Price
$351.79
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
2,596,556
0

Regeneron shares are up 2% after SunTrust upgrades the stock

9:41 am ET July 9, 2020 (MarketWatch)
Print

Shares of Regeneron Pharmaceuticals Inc. (REGN) were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to buy from hold, citing the strength of the company's drug pipeline. In a July 8 note to investors, they said that Regeneron's base business, which includes macular degeneration drug Eylea and atopic dermatitis therapy Dupixent, has remained strong during the COVID-19 pandemic. SunTrust analysts also said that the company's work on experimental COVID-19 therapies is an indicator of its "innovation engine." The company is currently testing (http://www.marketwatch.com/story/regenerons-stock-gains-on-450-million-manufacturing-deal-with-us-for-experimental-covid-19-treatment-2020-07-07) an experimental antibody cocktail candidate as a treatment for COVID-19 as well as to see if the therapy can prevent infection; however, Regeneron also said last week that a trial examining whether rheumatoid arthritis drug Kevzara, which Regeneron co-developed with Sanofi (SAN.FR), could work as a COVID-19 drug had failed in a late-stage study. Regeneron's stock has gained 72.9% year-to-date. The S&P 500 is down 1.8% for the year.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 09, 2020 09:41 ET (13:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.